While<unk>  is generally considered safe in a clinical setting, serious side effects from its use can occur. Most commonly,<unk>  can be injected into the wrong muscle group or with time spread from the injection site, causing temporary paralysis of unintended muscles. Side effects from cosmetic use generally result from unintended paralysis of facial muscles. These include partial facial paralysis, muscle weakness, and trouble swallowing. Side effects are not limited to direct paralysis, however, and can also include headaches, flu-like symptoms, and allergic reactions. Just as cosmetic treatments only last a number of months, paralysis side effects can have the same durations. At least in some cases, these effects are reported to dissipate in the weeks after treatment. Bruising at the site of injection is not a side effect of the<unk> , but rather of the mode of administration, and is reported as preventable if the clinician applies pressure to the injection site; when it occurs, it is reported in specific cases to last 7–11 days. When injecting the masseter muscle of the jaw, loss of muscle function can result in a loss or reduction of power to chew solid foods. With continued high doses, the muscles can atrophy or lose strength; research has shown that those muscles rebuild after a break from<unk> ox. Side effects from therapeutic use can be much more varied depending on the location of injection and the dose of<unk>  injected. In general, side effects from therapeutic use can be more serious than those that arise during cosmetic use. These can arise from paralysis of critical muscle groups and can include arrhythmia, heart attack, and in some cases, seizures, respiratory arrest, and death. Additionally, side effects common in cosmetic use are also common in therapeutic use, including trouble swallowing, muscle weakness, allergic reactions, and flu-like syndromes. In response to the occurrence of these side effects, in 2008, the FDA notified the public of the potential dangers of the<unk>  as a therapeutic. Namely, the<unk>  can spread to areas distant from the site of injection and paralyze unintended muscle groups, especially when used for treating muscle spasticity in children treated for cerebral palsy. In 2009, the FDA announced that boxed warnings would be added to available<unk>  products, warning of their ability to spread from the injection site. However, the clinical use of<unk>  A in cerebral palsy children has been proven to be safe with minimal side effects. Additionally, the FDA announced name changes to several<unk>  products, to emphasize that the products are not interchangeable and require different doses for proper use.<unk> ox and<unk> ox Cosmetic were given the INN of onabotulinumtoxinA, Myobloc as rimabotulinumtoxinB, and Dysport retained its INN of abobotulinumtoxinA. In conjunction with this, the FDA issued a communication to health care professionals reiterating the new drug names and the approved uses for each. A similar warning was issued by Health Canada in 2009, warning that<unk>  products can spread to other parts of the body.
Botulinum toxin
Bungarotoxin
Brevetoxin
Latrotoxin
Kurtoxin
Charybdotoxin
Tetrodotoxin
Α-Bungarotoxin